Kihealth, a company specializing in molecular diagnostics, announced it has won the Innovation of the Year challenge at the American Diabetes Association’s 85th Scientific Session held in Chicago. Kihealth’s liquid-biopsy test, which measures the rate of pancreatic betacell death, earned top honors among five finalists for its potential to revolutionize early diabetes detection
Dubbed the “Super Bowl of diabetes innovation,” this award has firmly established Kihealth and its products in the spotlight, the company touted. The honor follows a live pitch to a panel of expert judges and a global audience of clinicians, researchers and industry leaders. In winning first place, Kihealth stood out for delivering a novel diagnostic that provides patients and clinicians with a critical early window into metabolic health—years before glucose or A1C abnormalities.
The company touted the following key highlights and immediate impact:
- Surge in physician engagement: Following the win, Kihealth has received new contracts and strong interest from healthcare providers nationwide.
- Increased funding and partnerships: The recognition triggered follow-up discussions with institutional payers and wellness platforms exploring early-risk screening.
- Product visibility and credibility: The award signals clear validation of Kihealth’s molecular assay and commitment to elevating standards of preventive care.
“This is a monumental milestone,” said Jennifer Anderson, CEO of Kihealth. “Winning ADA’s Innovation of the Year at the 85th Scientific Sessions is the ultimate validation of our mission to enable earlier, more actionable insights into disease risk. It’s sparked tremendous momentum—from physician interest and contract discussions to expanded visibility. We’re just getting started.”
Media Contact:
Kihealth
Contact Person: Jenna Anderson
Email: press@kihealth.com